NASDAQ:APLM

Apollomics (APLM) Stock Price, News & Analysis

Apollomics logo
$16.51 -1.33 (-7.46%)
Closing price 03:58 PM Eastern
Extended Trading
$16.60 +0.08 (+0.51%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Apollomics Stock (NASDAQ:APLM)

Advanced

Key Stats

Today's Range
$16.61
▼
$17.87
50-Day Range
$16.51
▼
$25.54
52-Week Range
$12.58
▼
$28.29
Volume
9,592 shs
Average Volume
18,619 shs
Market Capitalization
$48.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Apollomics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer, with an emphasis on targeted therapies and immuno-oncology. The company has operated in the United States and China.

Its lead candidate, vebreltinib (APL-101), is an investigational, selective inhibitor of the MET protein being studied in cancers with alterations in the MET pathway, including certain lung cancers. Apollomics has also described additional investigational oncology candidates in its pipeline.

Apollomics’ drug candidates are in development and are not approved medicines. The company was founded in 2015; its programs are intended to address cancers for which existing treatment options may be limited.

AI Generated. May Contain Errors.

Apollomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

APLM MarketRank™: 
0.87581525356 of 5 stars

Apollomics scored higher than 18% of companies evaluated by MarketBeat, and ranked 806th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apollomics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Apollomics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Apollomics' stock forecast and price target.
    • Percentage of Shares Shorted

      0.19% of the float of Apollomics has been sold short.
    • Short Interest Ratio / Days to Cover

      Apollomics has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Apollomics has recently increased by 0.07%, indicating that investor sentiment is decreasing.
    • Dividend Yield

      Apollomics does not currently pay a dividend.

    • Dividend Growth

      Apollomics does not have a long track record of dividend growth.

    • News Sentiment

      Apollomics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
    • News Coverage This Week

      MarketBeat has tracked 1 news article for Apollomics this week, compared to 1 article on an average week.
    • MarketBeat Follows

      1 people have added Apollomics to their MarketBeat watchlist in the last 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Apollomics insiders have not sold or bought any company stock.

    • Percentage Held by Institutions

      19.13% of the stock of Apollomics is held by institutions.

    • Read more about Apollomics' insider trading history.
    Receive APLM Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    APLM Stock News Headlines

    Apollomics Reports First-Half 2026 Financial Results
    Apollomics Inc - Ordinary Shares - Class A
    You missed yesterday's deadline…
    In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
    Apollomics Inc
    Apollomics Inc. Class A
    Apollomics Regains Full Compliance with Nasdaq Listing Requirements
    See More Headlines

    APLM Stock Analysis - Frequently Asked Questions

    Apollomics' stock was trading at $18.69 at the start of the year. Since then, APLM stock has decreased by 11.7% and is now trading at $16.51.

    Apollomics Inc. (NASDAQ:APLM) issued its quarterly earnings data on Friday, November, 6th. The company reported ($2.02) earnings per share (EPS) for the quarter.

    Apollomics's stock reverse split on Monday, November 25th 2024.The 1-100 reverse split was announced on Thursday, November 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

    Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Company Calendar

    Last Earnings
    11/06/2026
    Today
    11/17/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:APLM
    CIK
    1944885
    Employees
    15
    Year Founded
    N/A

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.15
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    $8.50 million
    Price / Sales
    5.65
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($2.89) per share
    Price / Book
    -5.71

    Miscellaneous

    Outstanding Shares
    2,910,000
    Free Float
    N/A
    Market Cap
    $48.04 million
    Optionable
    Not Optionable
    Beta
    1.57
    7 Stocks to Buy Before the Robotics Revolution Cover

    Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

    Get This Free Report

    This page (NASDAQ:APLM) was last updated on 11/17/2026 by MarketBeat.com Staff.
    From Our Partners